Kenya Atopic Dermatitis Therapeutics Market Analysis

Kenya Atopic Dermatitis Therapeutics Market Analysis


$ 3999

The Kenya Atopic Dermatitis Therapeutics Market was valued at US $9 Mn in 2022, and is predicted to grow at (CAGR) of 9.9% from 2023 to 2030, to US $18 Mn by 2030. The key drivers of this industry include the rising prevalence of Atopic Dermatitis (AD), emergence of novel therapeutic options, and others. The industry is primarily dominated by players such as Sanofi, Pfizer, AbbVie, Astellas, Novartis, Eli Lilly, Galderma, and Leo Pharma, among others.

ID: IN10KEPH435 CATEGORY: Pharmaceuticals GEOGRAPHY: Kenya AUTHOR: Riddhi Solanki

Buy Now

Kenya Atopic Dermatitis Therapeutics Market Analysis: Executive Summary

The Kenya Atopic Dermatitis Therapeutics Market is at around US $9 Mn in 2022 and is projected to reach US $18 Mn in 2030, exhibiting a CAGR of 9.9% during the forecast period.

Atopic dermatitis (AD), commonly known as eczema, is a persistent inflammatory skin condition characterized by redness, itching, and inflammation. It often manifests in localized patches across various body areas and can be exacerbated by factors such as dry skin, stress, and exposure to specific irritants or allergens. Prominent symptoms include intense itching, redness, dryness, and the development of small, fluid-filled blisters that may discharge fluid and form crusts. Treatment typically involves a holistic approach, incorporating the use of emollients for skin moisturization, topical corticosteroids to reduce inflammation, and, in severe cases, systemic immunosuppressants. Several pharmaceutical companies manufacture medications for atopic dermatitis, with notable examples including Regeneron Pharmaceuticals and Sanofi's Dupixent (Dupilumab), Pfizer's Eucrisa (Crisaborole), and Novartis's Elidel (Pimecrolimus).

The projected prevalence of atopic dermatitis (AD) is on the rise, affecting approximately 20% of children in Kenya. The market is being propelled by significant factors such as the increasing prevalence of AD, emergence of novel treatment options in the therapeutics industry and other. However, conditions such as high costs of treatment, challenges in the healthcare system and lack of awareness about AD in the Kenyan population limit the growth and potential of the market.

Kenya Atopic Dermatitis Therapeutics Market Analysis 2022 to 2030

Market Dynamics

Market Growth Drivers

Increasing prevalence of AD: Increasing urbanization and environmental shifts are playing a role in the escalating prevalence of atopic dermatitis in Kenya, especially among children. Estimates indicate that it affects as much as 20% of children in certain urban areas. The mounting disease burden generates a substantial demand for efficient treatment options.

Emergence of novel therapeutics: The introduction of advanced, safer, and more efficient treatments such as biologics and targeted therapies offers hopeful alternatives for individuals dealing with atopic AD. The ongoing advancements in the pharmaceutical sector have the potential to fuel long-term market growth. Additionally, local research and development initiatives aimed at creating more affordable and accessible therapeutics tailored to the Kenyan context can further enhance market expansion.

Others: The increasing trend towards urbanization and shifts in lifestyle, marked by heightened exposure to allergens and pollutants, may contribute to the growing incidence of atopic dermatitis. A growing emphasis on personalized medicine and customizing treatment plans to suit individual patients has the potential to result in improved outcomes and an increased demand for specialized therapeutics.

Market Restraints

High cost of treatment: A considerable segment of the Kenyan populace encounters financial limitations, making it challenging to afford fundamental medications, let alone specialized treatments for conditions like atopic dermatitis.

Health system challenges: In rural areas, healthcare facilities and well-trained healthcare professionals, especially dermatologists, are frequently lacking. This shortage impedes access to both diagnosis and treatment for atopic dermatitis. Additionally, there is unequal healthcare access as public healthcare infrastructure, although in existence, grapples with resource constraints and may not prioritize chronic skin conditions such as atopic dermatitis. Consequently, this situation can result in extended wait times and restricted access to specialist care.

Lack of awareness: In Kenya, atopic dermatitis is sometimes linked to social stigma and misunderstandings, resulting in underdiagnosis and delayed treatment. The lack of awareness among both patients and healthcare providers can exacerbate these challenges. Certain communities may turn to traditional medicine for managing atopic dermatitis, potentially causing delays or interfering with conventional treatment options.

Healthcare Policies and Regulatory Landscape

Kenya's healthcare regulatory landscape is overseen by the Pharmacy and Poisons Board (PPB), which operates under the Kenyan Ministry of Health. The PPB is the main regulatory authority responsible for ensuring the safety, quality, and efficacy of pharmaceuticals and healthcare products in Kenya. It plays a crucial role in the registration and licensing of drugs, overseeing manufacturing practices, and enforcing compliance with established standards. Companies aiming to introduce new pharmaceutical products to the Kenyan market must undergo the regulatory processes defined by the PPB, including the submission of detailed documentation on product safety, efficacy, and quality.

For new entrants in Kenya's healthcare market, understanding and navigating the regulatory environment is essential. Obtaining licenses for pharmaceutical products involves engaging with the PPB and adhering to the regulatory requirements set by the authority. The regulatory landscape in Kenya is designed to ensure public health and safety, emphasizing compliance with international standards.

Competitive Landscape

Key Players

  • Sanofi
  • Pfizer
  • AbbVie
  • Leo Pharma
  • Eli Lilly
  • Novartis
  • Teva Pharmaceuticals
  • Regeneron Pharmaceuticals
  • Astellas Pharma
  • Galderma

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

Kenya Atopic Dermatitis Therapeutics Market Segmentation

By Drug Class

  • Corticosteroids
  • Calcineurin Inhibitors
  • Immunosuppressants
  • Biologic Therapy
  • PDE-4 Inhibitor
  • Antibiotics
  • Antihistamines
  • Emollients

By Route of Administration

  • Topic
  • Oral
  • Injectable

By Severity type

  • Mild
  • Moderate
  • Severe

By Age Group

  • 18 years and below
  • 19 years and above

By Distribution channel

  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy
  • Dermatology Clinics
  • Others

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.​

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

  • Analyzing historical proprietary data collected from multiple projects.
  • Regularly updating our existing data sets with new findings and trends.
  • Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

  • Searching through academic conferences, published research, citations, and social media platforms
  • Collecting and compiling diverse data to build a comprehensive and detailed database
  • Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

  • Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
  • Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
  • Continuously refreshing our database to ensure that the information remains current and reliable.
  • Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

  • Merging historical data from secondary research with real-time data from primary research.
  • Conducting thorough data validation and cleansing to remove inconsistencies and errors.
  • Organizing data into a structured format that is easily accessible and usable for various applications.
  • Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.

To request a free sample copy of this report, please complete the form below.


We value your inquiry and offer free customization with every report to fulfil your exact research needs.


Last updated on: 08 March 2024
Updated by: Dhruv Joshi

Related reports (by category)


Related reports (by geography)


subscribe to our newsletter
up